Why the study?
Does clozapine re-exposure under cardiac monitoring allow for safe management of refractory schizophrenia in a patient with prior clozapine-associated dilated cardiomyopathy?
Does clozapine re-exposure under cardiac monitoring allow for safe management of refractory schizophrenia in a patient with prior clozapine-associated dilated cardiomyopathy?
Clozapine re-exposure under close cardiac monitoring may be a viable option in select patients with refractory schizophrenia who previously developed clozapine-associated dilated cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Suggests carefully monitored clozapine rechallenge may be feasible in select patients.
A 63-year-old woman with diabetes type II and a history of breast cancer was treated with clozapine for her refractory schizophrenia. She developed a dilated cardiomyopathy with an ejection fraction of 25%, a life-threatening event. The cause of heart failure could be multifactorial, with clozapine, family history, chemotherapy, diabetes type II and/or lithium as possible contributing risk factors. Clozapine was discontinued and the patient was referred to a hospice. Two weeks later, her heart failure slowly improved. Subsequently, she became extremely psychotic with a severe decline in quality of life. Therefore, it was decided to restart clozapine under cardiac monitoring. The patient's psychotic symptoms improved and her heart failure status remained stable for more than a year. Thereafter, a small deterioration was seen in cardiac function. In this case, re-exposure to clozapine was successful for at least 2 years.
No takes yet. Share an insight, caveat, or question.
Nederlof et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: